## ADVERTISEMENT

NOT FOR DISTRIBUTION OR ANNOUNCEMENT, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR ANNOUNCEMENT WOULD BE UNLAWFUL. IT IS PROHIBITED TO ISSUE, PUBLISH OR CIRCULATE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN ANY JURISDICTION WHERE DOING SO WOULD VIOLATE THE LAWS OF SAID JURISDICTION.

*Nicosia, July 15 2026*

## ANNOUNCEMENT

# Approval and publication of the Prospectus of XRYMA PLC for the admission to trading on Euronext Paris of all ordinary shares of nominal value €0.07 each in the capital of XRYMA PLC

XRYMA PLC (the **"Company"**) announces that on July 14, 2026 the Cyprus Securities and Exchange Commission (the **"CySEC"**) approved the prospectus of the Company (the **"Prospectus"**) regarding the admission to trading of the Company's ordinary shares (the **"Shares"**) on the regulated market of Euronext Paris, with trading on an unconditional basis currently expected to commence on Friday, July 24, 2026 [indicative].

The Prospectus, as approved by CySEC, will be available to the general public without charge in electronic form at:

- The website of the Company, https://www.xryma.com, from July 14, 2026;
- The website of the Investment Firm responsible for drawing up the Prospectus, Global Capital Securities and Financial Services Limited, https://www.globalcapital.com.cy, from July 14, 2026;
- The website of the CySEC, https://www.cysec.gov.cy, from July 15, 2026.

The admission of the Shares to trading on Euronext Paris is subject to the Company obtaining an approval by Euronext Paris.

### Expected timetable of principal events for admission to trading

The timetable below is indicative and may be adjusted, including potential acceleration or extension:

| | |
|---|---|
| Prospectus approval and publication: | July 14, 2026 |
| Expected commencement of trading of the Shares on Euronext Paris, if admission is approved: | July 24, 2026 [indicative] |

### Contact for additional information:

For more information, investors can contact during business days and hours:

**Media contact:**
PR & Media team
E-Mail: media@xryma.com
Tel: +357-22015740

**Investor Relations:**
Investor Relations team
E-Mail: investors@xryma.com
Tel: +357-22015740

The Prospectus has been drawn-up in the form of a single document within the meaning of Article 6(3) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017 (**"Prospectus Regulation"**), and prepared on the basis of Annex 1 and Annex 11 of the Commission Delegated Regulation (EU) 2019/980 of March 14, 2019 supplementing the Prospectus Regulation as regards the format, content, scrutiny and approval of the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Commission Regulation (EC) No. 2004/809, and the Cyprus Public Offer and Prospectus Laws of 2005 to 2019 to the extent that they are valid after the entry into force of the Prospectus Regulation.

The Company has requested CySEC to notify the approved Prospectus in accordance with the Prospectus Regulation to the Autorité des marchés financiers.

This Prospectus has been approved by the **CySEC**, in its capacity as the competent authority in Cyprus within the meaning of the Prospectus Regulation. The CySEC only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the quality of the Shares or of the Company. Investors should make their own assessment as to the suitability of investing in the Shares and should carefully study the Prospectus before making any investment decision related to the Shares in order to fully understand the potential risks and rewards associated with the decision to invest in the Shares.

**THIS DOCUMENT IS NOT A PROSPECTUS BUT AN ADVERTISEMENT UNDER THE PROSPECTUS REGULATION AND INVESTORS SHOULD NOT MAKE ANY INVESTMENT DECISIONS REGARDING ANY SHARES REFERRED TO HEREIN BASED ON THIS ADVERTISEMENT.**